MedPacto Financial Statements From 2010 to 2024
| 235980 Stock | KRW 4,650 50.00 1.06% |
Check MedPacto financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MedPacto's main balance sheet or income statement drivers, such as , as well as many indicators such as . MedPacto financial statements analysis is a perfect complement when working with MedPacto Valuation or Volatility modules.
MedPacto |
MedPacto Company Shares Owned By Institutions Analysis
MedPacto's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current MedPacto Shares Owned By Institutions | 5.45 % |
Most of MedPacto's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MedPacto is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 5.45% of MedPacto are shares owned by institutions. This is much higher than that of the sector and significantly higher than that of the Biotechnology industry. The shares owned by institutions for all Republic of Korea stocks is notably lower than that of the firm.
MedPacto Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MedPacto's current stock value. Our valuation model uses many indicators to compare MedPacto value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MedPacto competition to find correlations between indicators driving MedPacto's intrinsic value. More Info.MedPacto is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value MedPacto by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for MedPacto's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About MedPacto Financial Statements
MedPacto stakeholders use historical fundamental indicators, such as MedPacto's revenue or net income, to determine how well the company is positioned to perform in the future. Although MedPacto investors may analyze each financial statement separately, they are all interrelated. For example, changes in MedPacto's assets and liabilities are reflected in the revenues and expenses on MedPacto's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MedPacto. Please read more on our technical analysis and fundamental analysis pages.
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers MS-1601A that targets TRG1 for cancers and autoimmune diseases and vactosertib for solid tumors. MedPacto is traded on Korean Securities Dealers Automated Quotations in South Korea.
Pair Trading with MedPacto
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MedPacto position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MedPacto will appreciate offsetting losses from the drop in the long position's value.Moving together with MedPacto Stock
| 0.64 | 207940 | Samsung Biologics | PairCorr |
| 0.65 | 302440 | SK Bioscience | PairCorr |
| 0.82 | 144510 | Green Cross Lab | PairCorr |
Moving against MedPacto Stock
The ability to find closely correlated positions to MedPacto could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MedPacto when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MedPacto - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MedPacto to buy it.
The correlation of MedPacto is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MedPacto moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MedPacto moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MedPacto can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in MedPacto Stock
MedPacto financial ratios help investors to determine whether MedPacto Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedPacto with respect to the benefits of owning MedPacto security.